sever
acut
respiratori
syndrom
sar
infecti
diseas
characteris
substanti
morbid
mortal
first
recognis
outbreak
issu
global
alert
sar
march
receiv
report
china
guangdong
provinc
hong
kong
vietnam
regard
cluster
respiratori
ill
unknown
aetiolog
one
first
report
made
scientist
carlo
urbani
call
investig
case
pneumonia
unclear
aetiolog
hospit
hanoi
later
die
sar
follow
alert
probabl
sar
case
also
report
region
china
asian
countri
includ
singapor
taiwan
indonesia
thailand
philippin
countri
includ
canada
usa
germani
also
identifi
case
retrospect
sar
origin
guangdong
end
first
spread
region
asia
intern
travel
facilit
spread
contin
cumul
total
probabl
case
sar
record
period
novemb
juli
death
countri
soon
sar
identifi
new
diseas
initi
collabor
global
network
strive
work
togeth
identifi
aetiolog
agent
sar
unpreced
time
novel
coronavirussar
coronaviruswa
identifi
probabl
caus
agent
sar
figur
koch
principl
demonstr
fulfil
agent
viru
belong
coronaviru
familyenvelop
positivesens
rna
virus
associ
respiratori
diseas
human
be
anim
evid
suggest
sar
coronaviru
origin
sarslik
virus
anim
southern
chines
provinc
guangdong
frequent
implic
anim
himalayan
palm
civet
anim
found
food
market
eaten
delicaci
sar
coronaviru
organis
open
read
frame
orf
contain
approxim
nucleotid
total
sarscoronaviru
sequenc
deriv
differ
sar
epidem
phase
analys
genotyp
characterist
phase
identifi
differ
sarscoronaviru
orf
repres
typic
viral
gene
proteas
replicas
spike
envelop
membran
nucleocapsid
may
repres
potenti
therapeut
target
figur
common
infect
caus
coronavirus
infect
sar
coronaviru
induc
synthesi
cotermin
set
subgenom
mrna
target
caus
agent
sever
acut
respiratori
syndrom
sar
affect
individu
worldwid
respons
death
outbreak
coronaviru
unknown
outbreak
although
mani
differ
treatment
use
outbreak
none
implement
control
fashion
thu
optim
treatment
sar
unknown
sinc
outbreak
much
work
done
test
new
agent
sar
use
invitro
method
anim
model
addit
global
research
effort
focus
develop
vaccin
sar
effort
made
evalu
promis
treatment
vaccin
control
clinic
trial
anoth
sar
outbreak
occur
cell
laboratori
set
sar
coronaviru
abl
infect
macaqu
monkey
mice
ferret
domest
cat
clinic
sar
characteris
system
symptom
fever
myalgia
follow
respiratori
symptom
includ
nonproduct
cough
dyspnea
laboratori
find
includ
lymphopenia
chest
radiograph
commonli
exhibit
unilater
bilater
infiltr
approxim
case
deterior
requir
intub
mechan
ventil
overal
mortal
rate
report
howev
sar
mortal
rate
year
old
report
high
affect
children
seem
milder
symptom
report
death
time
outbreak
physician
share
person
experi
support
reject
variou
treatment
sar
rapid
progress
outbreak
multicentr
randomis
control
intervent
trial
possibl
success
variou
treatment
remain
larg
anecdot
thu
consensu
therapeut
strategi
yet
reach
sinc
outbreak
global
research
effort
focus
test
new
agent
sar
invitro
method
anim
model
addit
much
effort
place
develop
effect
vaccin
sar
review
summaris
clinic
experi
use
variou
treatment
outbreak
provid
overview
data
vitro
vivo
support
otherwis
effect
treatment
propos
sinc
outbreak
addit
summaris
progress
made
date
regard
sar
vaccin
summari
pharmacolog
agent
use
propos
treatment
sar
shown
figur
outbreak
suspect
sar
case
usual
treat
initi
broadspectrum
antibacteri
drug
effect
typic
bacteri
caus
acut
communityacquir
pneumonia
administr
broadspectrum
antibioticseg
respiratori
fluoroquinolon
secondgener
cephalosporin
thirdgener
cephalosporinsplu
macrolid
recommend
first
sign
sar
initi
featur
diseas
nonspecif
howev
sar
coronaviru
identifi
caus
agent
antibiot
may
withdrawn
evid
antibiot
clinic
benefici
treatment
sar
even
caus
agent
sar
discov
treatment
ribavirin
use
empir
treat
patient
sar
ribavirin
synthet
nucleosid
broadspectrum
antivir
activ
clinic
studi
assess
effect
ribavirin
sar
rang
anecdot
case
report
retrospect
case
seri
one
randomis
clinic
trial
multipl
treatment
arm
howev
none
studi
definit
determin
whether
ribavirin
effect
sar
case
report
case
seri
suggest
combin
treatment
includ
ribavirin
may
benefici
extent
howev
studi
effect
ribavirin
confound
concomit
use
agent
exampl
studi
describ
clinic
radiolog
improv
patient
treat
ribavirin
steroid
without
control
group
difficult
determin
whether
improv
result
ribavirin
steroid
combin
natur
cours
ill
one
studi
show
delay
initi
combin
therapi
ribavirin
steroid
among
risk
factor
associ
sever
complic
diseas
suggest
ribavirin
might
benefici
difficult
delin
role
delay
use
ribavirin
delay
use
steroid
result
randomis
clinic
studi
guangdong
involv
multipl
differ
treatment
arm
suggest
ribavirin
given
low
dose
mgday
less
effect
compar
earli
aggress
use
steroid
interferon
alfa
howev
lack
control
arm
studi
allow
one
make
definit
conclus
whether
ribavirin
posit
effect
sar
compar
treatment
invitro
test
show
ribavirin
abl
inhibit
sarscoronaviru
replic
clinic
achiev
concentr
find
combin
postmortem
find
demonstr
high
viral
load
patient
despit
treatment
ribavirin
suggest
ribavirin
effect
sar
coronaviru
like
small
benefici
effect
best
import
sideeffect
associ
ribavirin
use
consid
knowl
cowork
report
common
advers
event
peopl
suspect
probabl
sar
treat
ribavirin
peopl
evid
haemolyt
anaemia
hypocalcaemia
hypomagnesaemia
report
peopl
respect
combin
proteas
inhibitor
lopinavir
ritonavir
use
less
frequent
sar
outbreak
compar
ribavirin
lopinavir
ritonavir
combin
first
consid
potenti
use
treatment
invitro
studi
show
antivir
activ
sar
coronaviru
chan
colleagu
compar
outcom
peopl
receiv
lopinavirritonavir
initi
treatment
rescu
therapi
match
control
patient
given
ribavirin
steroid
accord
standardis
protocol
addit
lopinavirritonavir
initi
treatment
associ
statist
signific
reduct
overal
death
rate
intub
rate
compar
match
control
howev
subgroup
receiv
lopinavirritonavir
rescu
therapi
show
signific
differ
endpoint
chu
cowork
also
assess
treatment
lopinavirritonavir
compar
histor
control
patient
also
treat
ribavirin
steroid
similar
protocol
chan
collegu
advers
event
develop
acut
respiratori
distress
syndrom
ard
death
within
day
significantli
lower
lopinavirritonavir
group
histor
control
addit
signific
reduct
need
rescu
puls
steroid
sever
respiratori
deterior
significantli
lower
nosocomi
infect
also
note
treat
lopinavirritonavir
compar
control
multivari
analysi
demonstr
lack
treatment
lopinavirritonavir
age
year
old
greater
posit
hepat
b
carrier
statu
independ
predictor
advers
outcom
includ
death
develop
ard
requir
intens
care
within
day
onset
ill
base
studi
lopinavirritonavir
appear
promis
antisarscoronaviru
agent
proteas
inhibitor
studi
vitro
potenti
antivir
effect
sar
exampl
yamamoto
colleagu
screen
set
compound
includ
antivir
drug
alreadi
wide
use
found
nelfinavir
strongli
inhibit
sarscoronaviru
replic
nelfinavir
inhibit
cytopath
effect
induc
sarscoronaviru
infect
express
viral
antigen
much
lower
infect
cell
treat
nelfinavir
untreat
infect
cell
addit
barnard
colleagu
found
two
proteas
inhibitorscalpain
inhibitor
vi
valleucho
calpain
inhibitor
iii
zvalphealacho
inhibit
sar
coronaviru
suggest
proteas
inhibitor
may
also
use
treatment
sar
membraneassoci
carboxypeptidas
angiotensinconvert
enzym
cellular
receptor
sar
coronaviru
interact
domain
spike
protein
thu
peptid
small
compound
bind
possibl
agent
treatment
prevent
sar
addit
solubl
form
receptor
antibodi
receptorbind
domain
spike
protein
may
candid
treatment
inde
sui
cowork
search
nonimmun
human
antibodi
librari
success
identifi
human
monoclon
antibodi
potent
neutralis
sarscoronaviru
infect
effici
inhibit
syncytium
format
block
bind
shown
compet
solubl
associ
domain
spike
protein
bound
high
affin
theoret
reason
invitro
evid
suggest
fusion
inhibitor
promis
treatment
candid
sar
peptid
deriv
heptad
repeat
region
transmembran
protein
involv
fusion
hiv
target
cellsar
basi
antihiv
fusion
inhibitor
base
similar
heptad
repeat
region
heptad
region
spike
protein
sar
coronaviru
common
mechan
mediat
fusion
viru
targetcel
membran
postul
liu
colleagu
test
two
set
peptid
correspond
heptad
region
spike
protein
inhibitori
activ
sar
coronaviru
found
one
sarscoronaviru
infect
vitro
postul
bind
heptad
region
spike
protein
interfer
conform
chang
need
allow
fusion
target
cell
rna
interfer
rnai
treatment
process
small
interf
rna
sirna
administ
lead
degrad
mrna
ident
sequenc
specif
technolog
use
silenc
gene
cultur
cell
anim
target
hiv
hepat
b
hepat
c
viral
infect
explor
possibl
interrupt
sarscoronaviru
replic
sirna
specif
sirna
target
spike
gene
sar
coronaviru
synthesis
sirna
effect
specif
inhibit
gene
express
spike
protein
sarscoronavirusinfect
cell
anoth
studi
assess
invitro
efficiaci
six
sirna
molecul
target
differ
site
replicas
region
sarscoronaviru
genom
judg
morpholog
chang
three
molecul
markedli
inhibit
cytopath
effect
caus
viral
infect
replic
three
sirna
also
inhibit
infect
replic
differ
strain
sar
coronaviru
indic
sirna
target
replicas
region
may
option
futur
clinic
use
invitro
studi
shown
glycyrrhizin
compon
liquoric
root
abl
inhibit
sarscoronaviru
replic
glycyrrhizin
inhibit
hiv
replic
vitro
use
clinic
treatment
hepat
c
hepat
b
success
mechan
glycyrrhizininduc
inhibit
viral
replicationand
specif
sarscoronaviru
replicationi
unclear
possibl
involv
inhibit
replic
antivir
effect
nitric
oxid
glycyrrhizin
upregul
express
induc
synthas
product
mous
macrophag
addit
preliminari
result
cinatl
colleagu
show
glycyrrhizin
induc
synthas
vero
cell
use
cultiv
sar
coronaviru
cinatl
colleagu
show
sarscoronaviru
replic
inhibit
deta
nonoatea
donor
compoundi
ad
cultur
medium
find
corrobor
keyaert
cowork
use
differ
donor
compound
snitrosonacetylpenicillamin
keyaert
colleagu
also
report
find
use
inhal
ga
treat
number
peopl
sar
result
suggest
associ
immedi
improv
oxygen
last
effect
termin
inhal
known
potent
mediat
airway
inflamm
niclosamid
wu
colleagu
screen
set
market
drug
regist
antivir
use
determin
invitro
activ
sar
coronaviru
found
niclosamid
exist
antihelmint
drug
abl
inhibit
replic
sar
coronaviru
underli
mechan
drug
exert
effect
unclear
studi
show
niclosamid
interfer
virion
attach
entri
cell
appear
inhibit
proteas
activ
new
compound
continu
test
goal
find
potenti
candid
treatment
sar
exampl
agent
test
wu
colleagu
found
compound
potent
antisarscoronaviru
activ
compound
like
discov
futur
sar
outbreak
system
steroid
becam
mainstay
sar
therapi
mani
centr
rational
use
base
paradox
find
despit
fall
sarscoronaviru
viral
load
rise
sarsspecif
igg
typic
seen
week
ill
clinic
deterior
observ
peopl
addit
patholog
find
consist
bronchiol
obliteran
organis
pneumonia
ard
led
hypothesi
immun
hyperact
result
cytokin
dysregul
may
compon
sar
could
reduc
steroid
treatment
case
steroid
administ
adjunct
therapi
ribavirin
treatment
patient
review
respiratori
condit
worsen
clinic
puls
highdos
steroid
ad
howev
studi
confound
concomit
use
agent
none
studi
contain
control
group
thu
whether
steroid
benefici
effect
treatment
sar
readili
determin
studi
treatment
regimen
contain
steroid
seem
associ
chest
radiograph
improv
fever
defervesc
improv
oxygen
rate
earlier
patient
treat
steroid
howev
studi
hsu
colleagu
ad
steroid
associ
clinic
improv
although
dose
steroid
studi
lower
benefit
seen
ho
cowork
retrospect
compar
clinic
radiograph
outcom
peopl
probabl
sar
receiv
ribavirin
initi
receiv
puls
highdos
steroid
initi
receiv
lowdos
steroid
puls
highdos
steroid
also
given
patient
rescu
therapi
presenc
deterior
respiratori
statu
cumul
steroid
dose
intens
care
unit
admiss
rate
need
mechan
ventil
mortal
rate
similar
group
day
howev
peopl
initi
given
puls
steroid
requir
less
oxygen
earlier
radiograph
improv
addit
requir
substanti
less
rescu
puls
steroid
studi
suggest
earli
initi
puls
steroid
may
role
treatment
sar
howev
definit
studi
need
potenti
benefit
steroid
must
compar
associ
risk
develop
avascular
necrosi
secondari
sepsi
fatal
aspergillosi
describ
peopl
sar
beij
hong
du
evalu
peopl
sar
receiv
steroid
ribavirin
present
largejoint
pain
potenti
caus
avascular
necrosi
march
may
plain
radiograph
magnet
reson
imag
examin
complet
day
peopl
identifi
avascular
necrosi
mean
time
diagnosi
avascular
necrosi
day
onset
sar
day
steroid
use
interferon
type
interferon
shown
inhibit
sarscoronaviru
replic
invitro
studi
initi
report
describ
invitro
result
interferon
use
clinic
latter
part
outbreak
loutfi
colleagu
describ
clinic
experi
interferon
alfacon
recombin
nonnatur
occur
type
interferon
contain
common
aminoacid
sever
natur
interferon
alfa
subtypesin
peopl
probabl
sar
treat
openlabel
studi
toronto
peopl
sar
receiv
treatment
steroid
alon
compar
nine
peopl
receiv
steroid
plu
interferon
alfacon
group
treat
interferon
alfacon
significantli
improv
oxygen
satur
level
rapid
resolut
radiograph
lesion
addit
group
exhibit
substanti
less
elev
creatin
kinas
level
trend
toward
rapid
normalis
lactat
dehydrogenas
level
howev
group
also
receiv
higher
dose
steroid
difficult
determin
whether
benefici
effect
due
interferon
alfacon
haagman
cowork
investig
prophylact
use
interferon
macaqu
model
day
inocul
sar
coronaviru
macaqu
given
pegyl
interferon
alfa
substanti
reduc
viral
replic
viral
excret
viral
antigen
express
type
pneumocyt
pulmonari
damag
note
treat
macaqu
compar
untreat
macaqu
postexposur
treatment
pegyl
interferon
alfa
yield
intermedi
result
result
suggest
interferon
role
treatment
sar
patient
develop
antibodi
sar
coronaviru
surviv
diseas
passiv
activ
immunis
view
possibl
effect
mean
prevent
andor
treat
sar
inde
develop
variou
vaccin
one
import
goal
ongo
sar
research
one
initi
propos
treat
sar
use
sera
peopl
convalesc
sar
passiv
immunotherapi
passiv
immunis
attempt
anecdot
success
sinc
prior
infect
passiv
transfer
murin
neutralis
antibodi
shown
prevent
replic
sar
coronaviru
respiratori
tract
mice
technolog
advanc
enabl
develop
purif
human
monoclon
antibodi
exploit
creat
specif
monoclon
antibodi
largescal
product
inde
monoclon
antibodi
obtain
immortalis
b
lymphocyt
isol
convalesc
peopl
sar
shown
neutralis
viru
infect
vitro
prevent
viru
replic
mous
model
sarscoronaviru
infect
addit
ter
meulen
colleagu
show
prophylact
administr
human
igg
monoclon
antibodi
reactiv
whole
inactiv
sar
coronaviru
abl
reduc
replic
sar
coronaviru
lung
infect
ferret
complet
prevent
develop
sarscoronavirusinduc
macroscop
lung
patholog
stop
shed
viru
pharyng
secret
although
passiv
immunis
strategi
appear
promis
ideal
approach
ensur
rapid
control
futur
outbreak
sar
gener
effect
safe
vaccin
numer
team
worldwid
work
creation
vaccin
use
inactiv
sar
coronaviru
recombin
subunit
recombin
dna
viral
vector
given
potenti
antibodydirect
viral
enhanc
diseas
exacerb
report
vaccin
direct
anoth
coronaviru
felin
infecti
periton
coronaviru
import
vaccin
creat
care
evalu
use
clinic
vaccin
develop
work
relat
viralvector
vaccin
dna
vaccin
date
three
differ
viralvector
vaccin
describ
success
result
report
anim
model
gao
colleagu
report
use
three
adenoviralbas
vector
express
codonoptimis
sarscoronaviru
spike
membran
nucleocapsid
protein
intramuscular
vaccin
three
vaccin
day
day
shown
induc
broad
virusspecif
immun
rhesu
macaqu
six
vaccin
macaqu
antibodi
respons
spike
protein
tcell
respons
nucleocapsid
protein
addit
vaccin
anim
show
strong
neutralisingantibodi
respons
sarscoronaviru
infect
vitro
challeng
test
determin
whether
immun
respons
abl
prevent
reduc
sever
infect
sar
coronaviru
complet
bisht
cowork
construct
recombin
form
highli
attenu
modifi
vaccinia
viru
ankara
mva
contain
gene
encod
fulllength
sarscoronaviru
spike
protein
assess
whether
express
spike
protein
alon
mva
could
rais
neutralis
antibodi
protect
immunis
mice
intranas
intramuscular
administr
vaccin
balbc
mice
week
led
product
serum
antibodi
spike
protein
neutralis
sar
coronaviru
vitro
week
second
immunis
vaccin
anim
control
anim
challeng
sar
coronaviru
given
vaccin
reduc
titr
sar
coronaviru
respiratori
tract
likewis
passiv
transfer
serum
mice
immunis
vaccin
naiv
mice
led
reduct
sarscoronaviru
replic
find
suggest
mvabas
vaccin
promis
sarscoronaviru
vaccin
candid
bukreyev
colleagu
report
success
experi
mucos
immunis
african
green
monkey
attenu
parainfluenza
viru
express
sarscoronaviru
spike
protein
complet
sarscoronaviru
spike
protein
gene
incorpor
recombin
attenu
parainfluenza
viru
develop
live
attenu
intranas
paediatr
vaccin
human
parainfluenza
viru
type
four
african
green
monkey
vaccin
singl
dose
vaccin
administ
via
respiratori
tract
four
monkey
vaccin
control
monkey
challeng
sar
coronaviru
day
immunis
neutralis
serum
antibodi
note
vaccin
anim
sarscoronaviru
challeng
viral
shed
document
control
anim
vaccin
anim
author
conclud
vector
mucos
vaccin
express
sarscoronaviru
spike
protein
alon
may
highli
effect
prevent
sar
singledos
format
dna
vaccin
also
attract
option
sar
vaccin
thu
far
three
experiment
studi
publish
address
dna
vaccin
sar
yang
colleagu
show
give
mice
sarscoronaviru
dna
vaccin
encod
spike
glycoprotein
induc
tcell
respons
neutralisingantibodi
respons
protect
immun
altern
form
spike
protein
assess
found
induc
substanti
neutralisingantibodi
titr
strong
immun
respons
mediat
cell
addit
reduct
viral
replic
lung
six
order
magnitud
note
sarscoronaviru
challeng
protect
shown
mediat
humor
tcelldepend
immun
mechan
find
show
dna
vaccin
base
spike
glycoprotein
may
lead
effect
immun
respons
protect
immun
anim
model
kim
cowork
report
gener
characteris
dna
vaccin
target
nucleocapsid
protein
sar
coronaviru
antigen
linkag
calreticulin
shown
enhanc
mhc
class
present
cell
murin
model
shown
vaccin
dna
vaccin
lead
gener
potent
nucleocapsidspecif
humor
tcellmedi
immun
respons
compar
nucleocapsid
dna
alon
addit
mice
vaccin
dna
vaccin
capabl
substanti
reduc
titr
challeng
vaccinia
viru
express
sarscoronaviru
nucleocapsid
protein
similar
studi
zhu
colleagu
immunis
mice
nucleocapsidbas
dna
vaccin
led
nucleocapsidspecif
antibodi
specif
cytotox
tcell
activ
challeng
test
complet
togeth
data
present
potenti
vaccin
reflect
enorm
intern
effort
vaccin
usual
take
year
clinic
develop
review
enter
phase
clinic
trial
licens
expect
vaccin
avail
clinic
use
near
futur
howev
given
pace
amount
progress
date
period
time
clinic
product
sar
vaccin
may
substanti
shorten
compar
vaccin
whether
sar
reemerg
matter
debat
howev
event
sar
recur
promisingand
immedi
availableag
treatment
syndrom
seem
type
interferon
steroid
lopinavirritonavir
base
avail
data
agent
alreadi
clinic
approv
howev
time
anoth
outbreak
arriv
mani
promis
agentseg
sarscoronavirusspecif
receptorbind
inhibitor
fusion
inhibitor
sirnasmay
approv
clinic
use
choic
agent
need
determin
base
avail
data
time
ideal
promis
agent
would
given
control
clinic
trial
difficulti
design
implement
control
clinic
trialswhich
limit
abil
research
trial
past
sar
outbreak
continu
pose
problem
event
futur
outbreak
sar
novel
pathogenshav
summaris
best
solut
facilit
implement
clinic
trial
futur
outbreak
would
establish
intern
collabor
clinicaltri
group
access
appropri
conting
fund
intern
accept
ethic
review
board
research
base
invitro
studi
invivo
anim
model
continu
determin
best
agent
combin
agent
worthi
clinic
consider
declar
conflict
interest
data
review
identifi
search
medlin
current
content
refer
relev
articl
numer
articl
identifi
search
extens
file
author
search
term
sever
acut
respiratori
syndrom
sar
treatment
coronaviru
infect
sar
coronaviru
vaccin
antivir
english
languag
paper
review
